Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celsion Corp announces positive interim data from phase 2 dignity trial in breast cancer


Thursday, 27 Feb 2014 04:05pm EST 

Celsion Corp:Says positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer (RCWBC).Trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia.Based on data available to date, a local response rate of 80 pct has been observed in the 5 evaluable patients with refractory disease, notably 2 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).These data are consistent with the previously reported positive Phase 1 data in RCWBC. 

Company Quote

2.35
-0.07 -2.89%
22 Dec 2014